{
    "root": "6529cd98-61bf-430c-8001-c591d52dfa23",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Buprenorphine and Naloxone",
    "value": "20240112",
    "ingredients": [
        {
            "name": "BUPRENORPHINE HYDROCHLORIDE",
            "code": "56W8MW3EN1"
        },
        {
            "name": "NALOXONE HYDROCHLORIDE DIHYDRATE",
            "code": "5Q187997EE"
        },
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X"
        },
        {
            "name": "POVIDONE K30",
            "code": "U725QWY32X"
        },
        {
            "name": "ACESULFAME POTASSIUM",
            "code": "23OV73Q5G9"
        },
        {
            "name": "ANHYDROUS CITRIC ACID",
            "code": "XF417D3PSL"
        },
        {
            "name": "TRISODIUM CITRATE DIHYDRATE",
            "code": "B22547B95K"
        },
        {
            "name": "MANNITOL",
            "code": "3OWL53L36A"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "CORN SYRUP",
            "code": "9G5L16BK6N"
        },
        {
            "name": "MALTODEXTRIN",
            "code": "7CVR7L4A2D"
        },
        {
            "name": ".ALPHA.-TOCOPHEROL",
            "code": "H4N855PNZ1"
        },
        {
            "name": "FD&C YELLOW NO. 6",
            "code": "H77VEI93A8"
        },
        {
            "name": "STARCH, CORN",
            "code": "O8232NY3SJ"
        }
    ],
    "indications": "Buprenorphine and naloxone sublingual tablets are indicated for maintenance treatment of opioid dependence. Buprenorphine and naloxone sublingual tablets should be used as part of a complete treatment plan that includes counseling and psychosocial support.",
    "contraindications": "Prescription use of this product is limited under the Drug Addiction Treatment Act. ( 2.1 ) Administer buprenorphine and naloxone sublingual tablet sublingually as a single daily dose. ( 2.2 ) Strongly consider prescribing naloxone at the time buprenorphine and naloxone sublingual tablet is initiated or renewed because patients being treated for opioid use disorder have the potential for relapse, putting them at risk for opioid overdose. ( 2.3 ) To avoid precipitating withdrawal, induction with buprenorphine sublingual tablets should be undertaken when objective and clear signs of withdrawal are evident. After induction, doses of buprenorphine and naloxone sublingual tablets should be progressively adjusted to a level that holds the patient in treatment and suppresses opioid withdrawal signs and symptoms ( 2.4 ) The recommended target dosage of buprenorphine and naloxone sublingual tablet for maintenance is 16/4 mg. ( 2.4 ) Administer buprenorphine and naloxone sublingual tablets as directed in the Full Prescribing Information. ( 2.4 , 2.5 ) When discontinuing treatment, gradually taper to avoid signs and symptoms of withdrawal. ( 2.8 )",
    "warningsAndPrecautions": "Buprenorphine and Naloxone Sublingual Tablet, USP is an orange, round flat faced beveled edge tablet debossed with an alphanumeric word identifying the product strength (RP on one side for each strength, and \"n8\" on 8 mg tablets), supplied in white HDPE bottles:\n                  NDC 63629-9483-01 (buprenorphine 8 mg and naloxone 2 mg/sublingual tablet; content expressed in terms of free base, equivalent to 8.64 mg buprenorphine hydrochloride USP and 2.44 mg naloxone hydrochloride dihydrate USP) – 30 tablets per bottle\n                  Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature].\n                  Store Buprenorphine and Naloxone Sublingual Tablets securely and dispose of properly [see PATIENT COUNSELING INFORMATION (17)].\n                  Repackaged/Relabeled by:Bryant Ranch Prepack, Inc.Burbank, CA 91504",
    "adverseReactions": "Buprenorphine and naloxone sublingual tablet is contraindicated in patients with a history of hypersensitivity to buprenorphine or naloxone as serious adverse reactions, including anaphylactic shock, have been reported [see Warnings and Precautions (5.9)]."
}